Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC
PR Newswire•03/11/2026•17:04 ET
0
Key Highlights
- ➤Cardiol (CRDL) establishes ATM program for up to US$75 million in common shares
- ➤Jefferies LLC appointed sales agent for Nasdaq market share sales
- ➤Proceeds may fund CardiolRx™ pericarditis development and CRD-38 clinical development
- ➤Company has no obligation to sell shares, so proceeds could be less than US$75 million
Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC PR Newswire
TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales agreement (the "ATM Agreement") with Jefferies LLC (the "Sales Agent") for an at-the-market offering program (the "ATM Program").
Get started
Create a free account to read the full story.